-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
September 2016
-
Global Nursing Impact of Immunotherapy in Lung Cancer
By Beth Eaby-Sandy, MSN, CRNP, OCN, Massey Nematollahi, RN, MScN, OCN, CON, Diana Borthwick, MSc, PGD, and Beth Ivimey, RN United States of America There are now 2 distinct immunotherapy drugs approved, nivolumab and pembrolizumab, for the treatment of NSCLC after failure of platinum-based chemotherapy. Both nivolumab and pembrolizumab produce similar response rates and toxicity…
-
FDA’s New Tobacco Rule
By Kenneth Michael Cummings, PhD, MPH The US FDA recently finalized a new rule (http://www.fda.gov/TobaccoProducts/ Labeling/RulesRegulationsGuidance/ ucm388395.htm) that will extend its regulatory authority to all tobacco products, including small and large cigars, hookah tobacco (also called waterpipe tobacco), pipe tobacco, nicotine gels, dissolvable tobacco products, and electronic cigarettes (e-cigarettes). What will the new rule do?…
-
IASLC WCLC 2016: Active Prevention, Accurate Diagnosis, Advanced Care
Dear Colleagues, IASLC WCLC 2016, with the theme “Active Prevention, Accurate Diagnosis, Advanced Care,” will be a multidisciplinary conference covering all aspects of lung cancer. The conference will inform participants about the most recent scientific advances in the field of lung cancer and will provide updates on the state-of-the-art management of patients with lung cancer.…
-
Osimertinib: A New Option in Non-Small Cell Lung Cancer – Q&A with David R. Gandara, MD, and Federico Cappuzzo, MD, PhD
By Erik J. MacLaren, PhD Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), received FDA approval in November 2015 for use in patients with metastatic EGFR T790M non-small cell lung cancer (NSCLC) whose disease has progressed on other EGFR TKIs. Data presented in April 2016 at the European Lung Cancer Conference…
-
Victorian Comprehensive Cancer Centre
The Victorian Comprehensive Cancer Centre, which opened this summer, is a new purpose-built facility for cancer research, treatment, care, and education in Melbourne’s Parkville biomedical precinct. In addition to the new facilities, ten world-leading cancer organizations have come together to form the VCCC Alliance to share knowledge and resources and to drive the next generation…
-
Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD, PhD, and Ranee Mehra, MD
By Erik J. MacLaren, PhD Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line treatment for ALK-rearranged non-small cell lung cancer (NSCLC) after progression on the standard firstline therapeutic, crizotinib. Data from the J-ALEX trial,1 a Japanese phase 3 study directly comparing first-line efficacy…